Elera Nwogu
Medical · Glenarden, MDNPI 1497084131
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 512 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 512 payments — averaging $21.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Vanda Pharmaceuticals Inc.$958
- plus $4K from 18 others
What the payments were for
- Food & beverage$10,79899%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 62 | $1,347 |
| Alkermes, Inc. | 50 | $1,219 |
| Teva Pharmaceuticals USA, Inc. | 58 | $1,217 |
| Otsuka America Pharmaceutical, Inc. | 53 | $1,114 |
| Neurocrine Biosciences, Inc. | 48 | $1,086 |
| Vanda Pharmaceuticals Inc. | 46 | $958 |
| AbbVie | 54 | $915 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $796 |
| Johnson & Johnson | 18 | $453 |
| Almatica Pharma LLC | 11 | $255 |
| Supernus Pharmaceuticals, Inc. | 19 | $238 |
| E.r. Squibb & Sons, L.L.C. | 6 | $232 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $181 |
| Sunovion Pharmaceuticals Inc. | 11 | $162 |
| Eisai Inc. | 7 | $148 |
| Avanir Pharmaceuticals, Inc. | 8 | $141 |
| Corium, LLC | 4 | $109 |
| Axsome Therapeutics, Inc. | 5 | $105 |
| Bausch Health US, LLC | 3 | $71 |
| Jazz Pharmaceuticals Inc. | 4 | $70 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| TMS Neurohealth Centers Inc. | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,902 in reported general payments places this provider in the 95th percentile of 543 medical providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $105,327 |
| VraylarCariprazine Hcl | 23 | $36,500 |
| Aripiprazole | 110 | $11,841 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $8,961 |
| Adderall XrDextroamphetamine/Amphetamine | 12 | $4,323 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 40 | $4,203 |
| Quetiapine Fumarate | 213 | $2,676 |
| Bupropion XlBupropion Hcl | 58 | $2,282 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 56 | $2,122 |
| Clonazepam | 223 | $1,946 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 32 | $1,873 |
| Trazodone Hcl | 153 | $1,757 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 29 | $1,653 |
| Alprazolam | 262 | $1,548 |
| Duloxetine Hcl | 72 | $1,515 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,086 | $105,32711 claims |
| AbbVieVraylar | $915 | $36,50023 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $796 | $8,96115 claims |
| Almatica Pharma LLCSertraline Hcl | $255 | $516111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 medical providers in Maryland.
Other medical in Glenarden
- Victoria TrottStevensville$94K
- Sarah SagorskyBaltimore$68K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
- Kristina TrunnellFrederick$51K
- Karen ScottAnnapolis$49K
- Nicholas WunderAberdeen$40K
- Sarah JamiesonFrederick$34K
- Jayme WilliamsCatonsville$21K
- Megan PayneLutherville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.